BioLife Solutions, Inc.
BLFS
$25.41
-$1.09-4.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.58% | 21.13% | -5.35% | -26.02% | -57.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.58% | 21.13% | -5.35% | -26.02% | -57.70% |
| Cost of Revenue | 209.84% | 39.49% | -50.43% | -71.91% | -93.29% |
| Gross Profit | 20.76% | 17.48% | 15.99% | 3.87% | -5.58% |
| SG&A Expenses | 15.55% | -0.18% | -15.49% | -24.60% | -38.87% |
| Depreciation & Amortization | 46.77% | 1.35% | -25.80% | -41.56% | -74.29% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.37% | 3.53% | -26.64% | -41.13% | -66.03% |
| Operating Income | 57.41% | 87.27% | 92.60% | 85.83% | 93.58% |
| Income Before Tax | -771.17% | -15.97% | 61.60% | 58.05% | 102.62% |
| Income Tax Expenses | 130.85% | 29.00% | -97.98% | -704.17% | -337.90% |
| Earnings from Continuing Operations | -691.34% | -16.32% | 62.82% | 59.04% | 102.99% |
| Earnings from Discontinued Operations | 121.58% | 115.39% | 89.13% | 74.52% | -117.22% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.26% | 92.63% | 83.86% | 70.32% | 53.44% |
| EBIT | 57.41% | 87.27% | 92.60% | 85.83% | 93.58% |
| EBITDA | -35.70% | 982.60% | 158.08% | 133.94% | 126.97% |
| EPS Basic | 94.19% | 93.40% | 84.29% | 71.38% | 55.89% |
| Normalized Basic EPS | 162.25% | 103.15% | 95.76% | 86.37% | 93.75% |
| EPS Diluted | 92.91% | 92.78% | 83.58% | 70.72% | 55.89% |
| Normalized Diluted EPS | 159.94% | 102.76% | 95.56% | 86.21% | 93.75% |
| Average Basic Shares Outstanding | 3.88% | 4.41% | 4.91% | 5.37% | 5.56% |
| Average Diluted Shares Outstanding | 5.07% | 5.18% | 5.69% | 6.16% | 5.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |